NCT06491862 RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil
| NCT ID | NCT06491862 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Non-squamous Non-Small Cell Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2024-07-25 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2024-07-25 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with a/m non-squamous NSCLC with or without AGA and received at least 1 line of systemic treatment after failing PTC between January 2017 and December 2024.
Eligibility Criteria
Inclusion Criteria * Confirmed diagnosis of non-squamous NSCLC, Stage IIIB/IIIC incurable or IV/M1. * Age ≥ 18 years at diagnosis of advanced/metastatic disease. AGA Cohort: Presence of actionable mutations and all of the following: * failure of platinum-based chemotherapy, * failure of ≥ 1 line of approved target therapy or no targeted therapy available at the clinic, * additional systemic treatment after platinum + target therapy combination. Non-AGA Cohort: Absence of actionable mutations and all of the following: * failure of platinum-based chemotherapy, * failure of immunotherapy concurrent or sequential to platinum, * additional systemic treatment after platinum + immunotherapy combination. Exclusion Criteria * Patients with evidence of other primary malignancies (except basal cell carcinoma and melanoma) within 1 year prior to the index date will be excluded from both study cohorts. * Patients who participated in a clinical investigational study for the treatment of any cancer, including NSCLC, or any early access program from 2018 onwards.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06491862 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non-squamous Non-Small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06491862 currently recruiting?
Yes, NCT06491862 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT06491862 trial being conducted?
This trial is being conducted at Belo Horizonte, Brazil, Belo Horizonte, Brazil, Natal, Brazil, Porto Alegre, Brazil and 7 additional locations.
Who is sponsoring the NCT06491862 clinical trial?
NCT06491862 is sponsored by AstraZeneca. The trial plans to enroll 250 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.